Analysts expect that Aquestive Therapeutics Inc (NASDAQ:AQST) will announce earnings per share of ($0.67) for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for Aquestive Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.61) and the lowest estimate coming in at ($0.72). Aquestive Therapeutics posted earnings per share of ($1.90) during the same quarter last year, which would suggest a positive year over year growth rate of 64.7%. The firm is scheduled to report its next quarterly earnings report on Tuesday, September 3rd.
On average, analysts expect that Aquestive Therapeutics will report full year earnings of ($2.57) per share for the current financial year, with EPS estimates ranging from ($2.88) to ($2.25). For the next fiscal year, analysts expect that the company will report earnings of ($1.73) per share, with EPS estimates ranging from ($1.87) to ($1.58). Zacks’ earnings per share calculations are an average based on a survey of research firms that follow Aquestive Therapeutics.
Aquestive Therapeutics (NASDAQ:AQST) last announced its earnings results on Wednesday, May 8th. The company reported ($0.59) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.10). The company had revenue of $12.64 million during the quarter, compared to analysts’ expectations of $10.66 million.
A number of institutional investors have recently bought and sold shares of AQST. Citigroup Inc. increased its stake in Aquestive Therapeutics by 317.6% in the 1st quarter. Citigroup Inc. now owns 3,662 shares of the company’s stock valued at $25,000 after purchasing an additional 2,785 shares in the last quarter. New York State Common Retirement Fund purchased a new position in Aquestive Therapeutics in the 4th quarter valued at approximately $28,000. American International Group Inc. increased its stake in Aquestive Therapeutics by 109.7% in the 1st quarter. American International Group Inc. now owns 7,211 shares of the company’s stock valued at $50,000 after purchasing an additional 3,772 shares in the last quarter. Acadian Asset Management LLC purchased a new position in Aquestive Therapeutics in the 1st quarter valued at approximately $65,000. Finally, Spark Investment Management LLC purchased a new position in Aquestive Therapeutics in the 1st quarter valued at approximately $80,000. 66.21% of the stock is owned by institutional investors.
Shares of NASDAQ AQST traded down $0.01 during trading hours on Wednesday, reaching $4.19. The stock had a trading volume of 98,900 shares, compared to its average volume of 114,249. The stock has a market cap of $95.40 million and a PE ratio of -1.50. The company has a quick ratio of 1.71, a current ratio of 1.89 and a debt-to-equity ratio of 4.23. Aquestive Therapeutics has a fifty-two week low of $3.65 and a fifty-two week high of $20.70.
About Aquestive Therapeutics
Aquestive Therapeutics, Inc, a specialty pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; and Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery in the United States and internationally.
Recommended Story: What is the Current Ratio?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aquestive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquestive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.